Efectividad de la vacuna antineumocócica de 23 polisacáridos

The two fundamental points in which the vaccination may play a role are decrease in pneumococcal disease and reduction -up to 50%-70%- of the pneumococcal invasive disease, in persons older than 65 years, and from the economical point of view, different cost-effectiveness studies have been positive in these coherts.